Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at de gavnlige virkninger af Plavix er større end risiciene for patienter med risiko for aterotrombotiske hændelser.
The Committee for Medicinal products for Human Use (CHMP) decided that Plavix’ s benefits are greater than its risks for patients at risk of atherothrombotic events.